10-Q: Larimar Therapeutics Reports Q1 2025 Results, Highlights Progress in Friedreich's Ataxia Program

Larimar Therapeutics' Q1 2025 report highlights ongoing clinical trials for nomlabofusp in Friedreich's ataxia, including positive FDA feedback and plans for a Phase 3 study, alongside increased R&D spending and a net loss of $29.3 million.

Summary

• Larimar Therapeutics reported a net loss of $29.3 million for the three months ended March 31, 2025, compared to a net loss of $14.7 million for the same period in 2024.
• Research and development expenses increased to $26.6 million from $12.9 million year-over-year, driven by increased manufacturing and clinical trial costs.
• General and administrative expenses rose to $4.6 million from $3.8 million year-over-year.
• The company's cash, cash equivalents, and marketable securities totaled $157.5 million as of March 31, 2025, expected to fund operations into the second quarter of 2026.
• Larimar is advancing nomlabofusp, a treatment for Friedreich's ataxia (FA), through ongoing clinical trials, including a Phase 2 open label extension (OLE) trial and a pediatric PK run-in study.
• The FDA has provided positive feedback on the potential use of frataxin (FXN) concentration as a reasonably likely surrogate endpoint for nomlabofusp.
• Larimar plans to initiate a global Phase 3 study of nomlabofusp by mid-2025.
• The company amended the OLE protocol to administer premedication for the first month of dosing to reduce the risk of allergic reactions, including anaphylaxis.
• The company initiated dosing of adolescents (12-17 years old) in a pharmacokinetic ('PK') run-in study for pediatric patients with FA in January 2025.
• The company expects to provide an update on OLE data on at least 30 to 40 study participants in September 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported increased losses, it is making progress in clinical trials, has a clear path forward with regulatory interactions, and has sufficient cash to fund operations for the near term. However, the identification of anaphylaxis as a potential adverse reaction and the need for additional funding introduce risks.

Positives

• The FDA is open to considering FXN concentration as a reasonably likely surrogate endpoint, which could expedite the approval process for nomlabofusp.
• Larimar is on track to initiate a global Phase 3 study by mid-2025, demonstrating continued progress in clinical development.
• The company has a cash runway into the second quarter of 2026, providing financial stability for ongoing and planned activities.
• The FDA accepted the data supporting the comparability of the lyophilized drug product to the frozen solution and agreed with Larimar's plans to introduce the lyophilized product into its clinical development program in mid-2025.
• The company received access to the Medicines and Healthcare Regulatory Agency ('MHRA') Innovative Licensing and Access Pathway (ILAP) for the treatment of adults and children with FA.

Negatives

• The net loss increased significantly to $29.3 million in Q1 2025, reflecting higher R&D and G&A expenses.
• Anaphylaxis has been identified as an adverse drug reaction likely associated with nomlabofusp, requiring protocol amendments and potentially impacting patient safety.
• The company expects to see additional reactions related to anaphylaxis.
• The underlying performance criteria of the January 2025 PSU Awards were determined to be not probable of achievement, and no stock-based compensation expense was recognized for the three months ended March 31, 2025.

Risks

• The company is subject to risks and uncertainties common to pre-commercial companies in the biotechnology industry.
• There are uncertainties in obtaining successful non-clinical or clinical results that reliably and meaningfully demonstrate safety, tolerability and efficacy profiles that are satisfactory to the U.S. Food and Drug Administration (FDA), European Medicines Agency ('EMA') and other comparable regulatory authorities for marketing approval for nomlabofusp.
• There are potential delays in the commencement, enrollment and completion of clinical trials.
• The company's ability to raise sufficient additional capital on acceptable terms is not assured.
• Geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events may reduce the company's ability to access capital.

Future Outlook

Larimar anticipates that its current cash, cash equivalents and marketable securities will fund operations into the second quarter of 2026. The company plans to initiate a global Phase 3 study of nomlabofusp by mid-2025 and is targeting a BLA submission seeking accelerated approval by the end of 2025.

Management Comments

• Management expects to increase investment in research and development in order to advance nomlabofusp through additional clinical trials.
• Management expects that general and administrative expenses will increase in the foreseeable future as the company hires additional employees to implement, improve and scale operational, financial, commercial and management systems.

Industry Context

Larimar's focus on Friedreich's ataxia, a rare and progressive disease with limited treatment options, positions it within a high-need area of the pharmaceutical market. The FDA's willingness to consider surrogate endpoints could provide a significant advantage in accelerating the approval of nomlabofusp. The company's participation in the START pilot program and receipt of ILAP designation further underscores the regulatory support for its development efforts.

Comparison to Industry Standards

• Comparing Larimar to companies like Reata Pharmaceuticals (acquired by Biogen) and Biohaven (acquired by Pfizer), which also focused on neurological disorders, Larimar's progress in clinical trials and regulatory interactions appears promising.
• Reata's Skyclarys (omaveloxolone) approval for Friedreich's ataxia provides a benchmark for regulatory expectations and market potential in this space.
• However, the identification of anaphylaxis as a potential adverse reaction introduces a challenge that will require careful management and mitigation strategies, similar to how other companies have addressed safety concerns in their drug development programs.
• The company's cash runway into Q2 2026 is comparable to other biotech companies at a similar stage of development, but securing additional funding will be crucial for long-term success.

Related Party Transactions

• The Company entered into an agreement with the Friedreichs Ataxia Research Alliance (FARA) to join the TRACK-FA Neuroimaging Consortium that includes pharmaceutical, biotechnology, academic and clinical partners.
• One of the Company's Directors is also a director of FARA.

Stakeholder Impact

• Positive impact on patients with Friedreich's ataxia if nomlabofusp is approved.
• Potential impact on shareholders based on clinical trial results and regulatory decisions.
• Potential impact on employees based on the company's financial performance and strategic direction.

Next Steps

• Initiate a global Phase 3 study of nomlabofusp by mid-2025.
• Provide an update on OLE data on at least 30 to 40 study participants in September 2025.
• Continue interacting with the FDA under the START pilot program.
• Pursue a BLA submission seeking accelerated approval targeted for the end of 2025.

Key Dates

Keywords

nomlabofusp, Friedreich's ataxia, clinical trials, frataxin, FDA, Larimar Therapeutics, research and development, rare diseases, biotechnology, financial results